PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:

H.C. Wainwright 4th Annual Kidney Virtual Conference

Date:Monday, July 14, 2025
Time:1:30pm ET
Format:Fireside Chat
Webcast:



The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at . Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .

Investor Contacts:

ProKidney

Ethan Holdaway





LifeSci Advisors, LLC

Daniel Ferry



EN
09/07/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virt...

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference: H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate:Monday, July 14, 2025Time:1:30pm ETFormat:Fireside ChatWebcast: The live webc...

July 9, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Statistically and Clinically Significant Topline Res...

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the pe...

July 8, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Corp. Completes Domestication from the Cayman Islands to Del...

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports First Quarter 2025 Financial Results and Business Hi...

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDAEnded the first quarter with $328.5 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Cor...

May 12, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Full Year 2024 Financial Results and Business Highli...

ProKidney Reports Full Year 2024 Financial Results and Business Highlights Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-2025Full data from Group ...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch